"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

Urologists emphasized the importance of AUA guidelines, patient context, and clinical judgment in managing low-grade UTUC. Challenges in diagnosis and treatment include obtaining adequate biopsies and ...

WNT9B gene mutations significantly increase prostate cancer risk, with a 2- to 12-fold elevation observed across multiple studies. Specific variants, WNT9B E152K and Q47R, show significant ...

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares the initial and ...

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC ...

MPS2 test detects 94% of GG2 or higher prostate cancers using non-DRE urine samples, outperforming PSA and PCPTrc in accuracy. MPS2 models could reduce unnecessary biopsies by 36% to 42%, compared to ...

Signati's Separo system achieved FDA de novo market clearance application after demonstrating safety and effectiveness in GLP data and an IDE study. The Separo system enables a transdermal vasectomy, ...

Wilms tumor growth patterns differ based on the specific predisposition gene variant and its developmental timing. Around 30% of children with Wilms tumor have a mutation in a predisposition gene, ...

This video segment covers patient selection criteria for different versions of abiraterone, strategies for assessing treatment efficacy and safety, engaging caregivers to monitor compliance and side ...